3 terminated. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Terminated 3 |
Follow Nevi and Melanomas: new trials by email Literature Review of Nevi and Melanomas trials Research Report on Nevi and Melanomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies immune-checkpoint inhibitors therapies - Advanced or Metastatic Melanoma, Advanced or Metastatic NSCLC | Phase 4 | Terminated | Institut Paoli-Calmettes | 40 | 2019-10-16 | 2026-01-22 |
| HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma High Dose Interleukin-2, Ipilimumab - Metastatic Melanoma | Phase 4 | Terminated | Clinigen, Inc. | 29 | 2013-05-01 | 2023-12-05 |
| HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma vemurafenib + HD IL-2 - Metastatic Melanoma | Phase 4 | Terminated | Clinigen, Inc. | 53 | 2012-08-01 | 2021-02-01 |
Melanoma (3) · Skin Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasm Metastasis (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplastic Processes (1)
aldesleukin (2) · Interleukin-2 (1) · Interleukins (1) · Ipilimumab (1) · Vemurafenib (1)
Clinigen, Inc. (2) · Institut Paoli-Calmettes (1)
United States (2) · France (1)
James Lowder, MD (1) · Renaud Sabatier, MD (1) · Sapna Patel, MD (1) · Tharak Rao, MD (1) · William Sharfman, MD (1)
2018 (1)